ImmuPharma (LON:IMM) Trading Down 10% - Should You Sell?

Key Points

• ImmuPharma's share price fell by 10%, trading as low as GBX 10.51 ($0.14) on Monday, indicating significant market volatility.
• The company reported a negative return on equity of 131.41% and anticipates posting an EPS of -339 for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics, with its lead program Lupuzor™ targeting autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was down 10% on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares were traded during trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Price Performance

The company's 50 day simple moving average is GBX 4.46 and its two-hundred day simple moving average is GBX 3.33. The stock has a market capitalization of £56.23 million, a P/E ratio of -1,264.38 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, research analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.